Open AccessVirological and immunological impact of integrase inhibitor-based regimens initiated during primary HIV-1 infection
Author(s) -
Raphaël Veil,
Isabelle PoizotMartin,
Jacques Reynes,
Cécile Goujard,
Rémonie Seng,
Pierre Delobel,
Laurent Cotte,
Claudine Duvivier,
David Rey,
Laurent Tran,
Laure Surgers,
Clotilde Allavena,
Caroline Lascoux Combe,
Antoine Chéret,
Laurence Meyer
Publication year - 2020
Publication title -
aids
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.195
H-Index - 216
eISSN - 1473-5571
pISSN - 0269-9370
DOI - 10.1097/qad.0000000000002447
Subject(s) - cart , dolutegravir , integrase inhibitor , medicine , darunavir , confidence interval , integrase , viral load , cd4 cd8 ratio , human immunodeficiency virus (hiv) , cd8 , cohort , gastroenterology , antiretroviral therapy , immunology , virology , immune system , mechanical engineering , lymphocyte subsets , engineering
Current international guidelines recommend either boosted protease inhibitor (PI/r)-based or integrase inhibitors (INSTI)-based regimens during primary HIV infection (PHI), even though the latter have only demonstrated their superiority at the chronic stage. We compared the effectiveness of INSTI-based versus PI/r-based combined antiretroviral therapy (cART) initiated during PHI.